Rare Genetic Variants Significantly Increase ADHD Risk, New Study Reveals
Table of Contents
A groundbreaking new study published in Nature sheds light on the genetic underpinnings of attention deficit hyperactivity disorder (ADHD), identifying three specific genes linked to a substantially increased risk of the neurodevelopmental condition. The research offers hope for earlier diagnosis and more personalized treatment strategies.
New research published in July 2025 reveals how rare genetic variations contribute to the risk of ADHD, offering new insight into the biology behind this common neurodevelopmental condition.
Unraveling the Genetic Architecture of ADHD
ADHD affects approximately 5% of children and 2.5% of adults, yet the role of rare genetic variants in its development has remained largely unknown. While common genetic variants have been previously associated with the disorder, this study employed exome sequencing – a technique that focuses on the protein-coding regions of the genome – to analyze a large cohort of 8,895 individuals with ADHD and 53,780 control subjects. This comprehensive analysis revealed that uncommon genetic alterations can have a disproportionately large impact on risk.
Identifying Key Genes and Their Impact on Brain Function
Researchers pinpointed three significant genes – MAP1A, ANO8, and ANK2 – as playing a crucial role in ADHD susceptibility. These genes exhibited statistical significance (P < 3.07 × 10−6) and demonstrated odds ratios ranging from 5.55 to 15.13, indicating a strong association with the disorder.
The protein networks associated with these genes are heavily involved in critical brain functions, including synapse function, RNA processing, and cytoskeleton organization. Notably, the study found that rare, harmful variants were linked to an average decrease of 2.25 IQ points per variant in a sample of 962 adults with ADHD. Individuals with both ADHD and intellectual disability also showed a higher overall load of these genetic variants.
“These findings suggest a clear biological pathway linking specific genetic disruptions to cognitive outcomes in individuals with ADHD,” one analyst noted.
Furthermore, the research revealed a striking overlap with other neurodevelopmental conditions. Nine of the top 20 genes associated with ADHD have also been implicated in autism or other similar disorders. Most of these genes exhibit high levels of expression during both prenatal and postnatal brain development, suggesting a critical role in early brain formation. The study also confirmed that both rare and common variants contribute to ADHD risk in an additive manner, supporting a polygenic model of the disorder.
Implications for Diagnosis and Future Treatment
These discoveries have significant implications for clinical practice. Assessing rare variants could potentially refine diagnostic pathways, allowing clinicians to anticipate cognitive or developmental challenges associated with ADHD risk. As genetic sequencing becomes more affordable and accessible, genetic profiling may enable earlier intervention planning and more tailored educational support for children at risk.
Future research will focus on identifying additional genes involved in ADHD and clarifying how specific variant patterns influence clinical outcomes. This work aims to pave the way for more personalized approaches to neurodevelopmental care, offering hope for improved outcomes for individuals affected by ADHD.
The study, led by Demontis D et al., was published in Nature in July 2025 (DOI: 10.1038/s41586-025-09702-8).
